Labetalol to Prevent Hypertension and Tachycardia During Fiberoptic Bronchoscopy

Passing a bronchoscope through the airways frequently causes a stress response even though patients are sedated. This stress response is usually an increase in pulse and blood pressure, which may have undesirable effects on the heart and circulation.

We plan to give patients labetalol (a beta blocker which reduces pulse and blood pressure) in addition to normal sedation, to patients undergoing bronchoscopy in our department.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Bronchoscopy

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Rabin Medical Center

Petah Tikva, 49100, Israel

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

All patients over 18 years old undergo fiberoptic bronchoscopy in our unit

Exclusion criteria

inability or refusal to give informed consent
bronchoscopy through an artificial airway
intolerance or allergy to the study drug
bradycardia (HR<60/min) or hypotension (systolic BP <100) at screening
pregnancy,
concomitant treatment with diltiazem or verapamil
intention to use propofol as the sedative agent for bronchoscopy.

Treatment and study plan

Labetalol 10mg iv

Drug

Primary outcomes

Heart Rate
Systolic Blood Pressure
Diastolic Blood Pressure
Rate pressure product (HR*SBP/100)

Sponsors and collaborators

Lead sponsor

Rabin Medical Center

Other

Registry information

Important dates

Study completion: 2007
First posted: Nov 1, 2006
Registry last updated: Jun 6, 2007

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed